Compounds > 6,2',4'-trimethoxyflavone
Page last updated: 2024-12-09

6,2',4'-trimethoxyflavone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6,2',4'-trimethoxyflavone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID688802
SCHEMBL ID4915794
MeSH IDM0542982

Synonyms (22)

Synonym
6,2',4'-trimethoxyflavone
2-(2,4-dimethoxyphenyl)-6-methoxychromen-4-one
ST057638
720675-90-1
2-(2,4-dimethoxyphenyl)-2,3-dihydro-6-methoxy-4h-1-benzopyran-4-one
flavonid, 6[4,2]
bdbm93448
720675-74-1
SCHEMBL4915794
AKOS024282698
2',4',6-trimethoxyflavone
4h-1-benzopyran-4-one, 2-(2,4-dimethoxyphenyl)-6-methoxy-
WUWFDVDASNSUKP-UHFFFAOYSA-N
mfcd03412381
2-(2,4-dimethoxyphenyl)-6-methoxy-4h-chromen-4-one
DTXSID80350974
6, 2', 4'-trimethoxyflavone, >=98% (hplc)
FT-0750678
MS-24550
HY-103220
CS-0025311
PD001171
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cathepsin L2Homo sapiens (human)IC50 (µMol)50.00000.07502.214110.0000AID1799911
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
apoptotic processCathepsin L2Homo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IICathepsin L2Homo sapiens (human)
extracellular matrix disassemblyCathepsin L2Homo sapiens (human)
immune responseCathepsin L2Homo sapiens (human)
positive regulation of apoptotic signaling pathwayCathepsin L2Homo sapiens (human)
positive regulation of peptidase activityCathepsin L2Homo sapiens (human)
proteolysis involved in protein catabolic processCathepsin L2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
cysteine-type endopeptidase activityCathepsin L2Homo sapiens (human)
serine-type endopeptidase activityCathepsin L2Homo sapiens (human)
protein bindingCathepsin L2Homo sapiens (human)
cysteine-type peptidase activityCathepsin L2Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCathepsin L2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
extracellular regionCathepsin L2Homo sapiens (human)
lysosomal lumenCathepsin L2Homo sapiens (human)
extracellular spaceCathepsin L2Homo sapiens (human)
lysosomeCathepsin L2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1799911Inhibition Activity Assay from Article 10.1021/cc100076k: \\Solution phase synthesis of a combinatorial library of chalcones and flavones as potent cathepsin V inhibitors.\\2010Journal of combinatorial chemistry, Sep-13, Volume: 12, Issue:5
Solution phase synthesis of a combinatorial library of chalcones and flavones as potent cathepsin V inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.86 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
lactic acid
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.		2.13102-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
kynurenine
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.. kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.		2.5220aromatic ketone;
non-proteinogenic alpha-amino acid;
substituted aniline		human metabolite
benzo(a)pyrene
Benzo(a)pyrene: A potent mutagen and carcinogen. It is a public health concern because of its possible effects on industrial workers, as an environmental pollutant, an as a component of tobacco smoke.. benzo[a]pyrene : An ortho- and peri-fused polycyclic arene consisting of five fused benzene rings.		2.0510ortho- and peri-fused polycyclic arenecarcinogenic agent;
mouse metabolite
4-chlorobiphenyl
4-chlorobiphenyl : A monochlorobiphenyl carrying a chloro substituent at position 4.		2.1110monochlorobiphenyl
3,4,5,3',4'-pentachlorobiphenyl
3,3',4,4',5-pentachlorobiphenyl : A pentachlorobiphenyl in which the chlorines are located at the 3, 4, 5, 3', and 4' positions.		2.1110pentachlorobiphenyl;
trichlorobenzene
6-methoxy-2-(4-methoxyphenyl)-1-benzopyran-4-one
[no description available]		2.0510ether;
flavonoids
ConditionIndicatedRelationship StrengthStudiesTrials
Cerebral Infarction, Middle Cerebral Artery
[description not available]		02.110
Cerebral Ischemia
[description not available]		02.110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.110
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		02.110
Infarction, Middle Cerebral Artery
NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.		02.110